Northland Capmk Weighs in on MiMedx Group Q1 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Northland Capmk issued their Q1 2025 earnings estimates for MiMedx Group in a research note issued to investors on Friday, December 27th. Northland Capmk analyst C. Byrnes anticipates that the company will post earnings of $0.05 per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.

Separately, StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Up 0.6 %

Shares of NASDAQ:MDXG opened at $9.48 on Monday. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a market cap of $1.39 billion, a PE ratio of 17.24 and a beta of 1.98. The firm has a 50 day simple moving average of $8.35 and a 200 day simple moving average of $7.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently modified their holdings of the business. Paradigm Capital Management Inc. NY grew its position in MiMedx Group by 6.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after purchasing an additional 258,700 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of MiMedx Group by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock worth $16,518,000 after buying an additional 44,254 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in MiMedx Group by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after purchasing an additional 92,726 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of MiMedx Group by 47.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after acquiring an additional 413,443 shares during the period. Finally, Harbor Capital Advisors Inc. boosted its position in MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after purchasing an additional 770,744 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.